APTO•benzinga•
Aptose Reports Early Safety And Response Results In Phase 1/2 TUSCANY Trial Of Tuspetinib In Combination With Standard Of Care Dosing Of Venetoclax And Azacitidine; Says TUS+VEN+AZA Triplet Achieved Cycle 1 Complete Remission In TP53-Mutated/CK AML
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga